Follow AbbVie to never miss an important update.
AbbVie is teaming up with Valkai to integrate artificial intelligence into its clinical development, which is the long and expensive process of testing new drugs on people. This is the company's second AI partnership in two weeks, following a similar deal with Iambic to help discover new drug candidates.
By using AI to analyze data and manage trials, the company aims to find successful treatments faster and at a lower cost. For a business that relies on constantly filling its pipeline with new medicines to replace older ones, any technology that makes the research process more efficient is a meaningful long-term advantage.
Source: PRNewsWire
AbbVie has joined the Antibody Developability Consortium alongside other pharmaceutical firms like Takeda and Lundbeck. The group will work on ways to better predict which antibody-based drugs will be safe and effective before they enter expensive clinical trials. While this is a routine industry collaboration, it supports the company's focus on complex biologics, which are medicines made from living cells that are harder to copy than traditional pills.
Source: Business Wire
The U.S. Food and Drug Administration has approved a new AbbVie treatment for adults living with Parkinson's disease. This adds a fresh product to the company's neuroscience portfolio, which is a key area of focus as it looks for new sources of growth.
While the company is best known for its immunology drugs, expanding into neuroscience helps reduce its reliance on any single product. This approval is a positive step in proving the company can successfully bring new treatments to market to replace revenue from older drugs that now face cheaper competition.
Source: Reuters
European regulators have cleared Rinvoq to treat children with active polyarticular juvenile idiopathic arthritis, a condition that causes joint pain and swelling. This approval includes a new liquid version of the drug designed for younger patients.
This is the 11th approved use for Rinvoq in the European Union. Expanding the drug into more conditions and younger age groups is a key part of the company's plan to replace the revenue lost from its older blockbuster drug, Humira. While this specific patient group is small, it adds to the drug's momentum as a versatile treatment for immune-related diseases.
Source: PRNewsWire
AbbVie is partnering with Iambic to use its artificial intelligence platform to find and develop new small-molecule drugs more quickly. The multi-year deal focuses on the company's core areas, including immunology, neuroscience, and oncology.
Drug discovery is a slow and expensive process where researchers test thousands of compounds to find one that works. By using AI to predict how molecules will behave, AbbVie aims to shorten this cycle and find more effective treatments. This is a smart move to keep its pipeline full as it looks for new sources of growth beyond its older blockbuster drugs.
Source: PRNewsWire
Management consistently sets a predictable bar and clears it by a small margin. This steady record of beats shows they have a firm handle on their business even while replacing their biggest drug.
| Expectation | |
|---|---|
| EPS | $3.86 |
| Revenue | $17.31B |